Trends in Human Papillomavirus Vaccination in Commercially Insured Children in the United States.

Autor:	Chen ST; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts; and szutachen@alumni.harvard.edu., Huybrechts KF; Division of Pharmacoepidemiology and Pharmacoeconomics, Departments of Medicine and., Bateman BT; Division of Pharmacoepidemiology and Pharmacoeconomics, Departments of Medicine and.; Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Harvard University, Boston, Massachusetts., Hernández-Díaz S; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts; and.
Jazyk:	angličtina
Zdroj:	Pediatrics [Pediatrics] 2020 Oct; Vol. 146 (4). Date of Electronic Publication: 2020 Sep 14.
DOI:	10.1542/peds.2019-3557
Abstrakt:	Objectives: The human papillomavirus (HPV) vaccine was recommended in 2006 for girls and in 2011 for boys. The Healthy People 2020 goal for 2-dose HPV vaccination coverage is 80% by age 15 for girls and boys. We used nationwide population-based data to describe trends in HPV vaccination in children. Methods: We conducted a cohort study nested within the MarketScan health care database between January 2003 and December 2017. Children were followed from the year they turned 9 until HPV vaccination, insurance disenrollment, or the end of the year when they turned 17, whichever came first. We estimated the cumulative incidence of at least 1- and 2-dose HPV vaccination, stratified by birth year, sex, and state. In secondary analyses, we evaluated the association between state-level vaccination policies and HPV vaccination coverage. Results: This study included 7 837 480 children and 19.8 million person-years. The proportion of 15-year-old girls and boys with at least a 1-dose HPV vaccination increased from 38% and 5% in 2011 to 57% and 51% in 2017, respectively; the proportion with at least a 2-dose vaccination went from 30% and 2% in 2011 to 46% and 39% in 2017, respectively. By 2017, 2-dose HPV vaccination coverage varied from 80% in Washington, District of Columbia, among girls to 15% in Mississippi among boys and was positively correlated with legislation for HPV vaccine education and pediatrician availability. Conclusions: Despite the increasing trends in uptake, HPV vaccine coverage among commercially insured children in the United States remains behind target levels, with substantial disparities by state. Competing Interests: POTENTIAL CONFLICT OF INTEREST: Dr Hernández-Díaz reports research grants to her institution from GlaxoSmithKline and Eli Lilly and consulted for Roche and UCB for unrelated projects. Dr Bateman reports research grants to his institution from Pfizer, GlaxoSmithKline, Eli Lilly, Baxalta, and Pacira for unrelated projects; he was a consultant on a perinatal quality improvement project sponsored by Merck for Mothers. Krista F. Huybrechts reports research grants to her institution from Boehringer Ingelheim, Pfizer, Eli Lilly, and GlaxoSmithKline for unrelated projects; and Dr Chen has indicated he has no potential conflicts of interest to disclose. (Copyright © 2020 by the American Academy of Pediatrics.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu